The humoral immunity after SARS-CoV-2 infection or vaccination was examined.
Convalescent sera after infection with variants of concern (VOCs: B. 1.1. 7, n= 10; B. 1.351 …

Background The humoral immune response after primary immunisation with a SARS-CoV-2
vector vaccine (AstraZeneca AZD1222, ChAdOx1 nCoV-19, Vaxzevria) followed by an …

Background Vaccination against COVID-19 was implemented very quickly, but the
emergence of new variants that can evade the previous acquired immunological protection …

The new WHO reference standard allows for the definition of serum antibodies against
various SARS-CoV-2 antigens in terms of binding antibody units (BAU/mL) and thus to …

Background Few studies have directly compared virus-specific antibodies and their
neutralizing capacity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV …

Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid
(mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute …

Since the first detection of a novel Coronavirus (SARS-CoV-2) in December 2019 in Wuhan
(China), it has become crucial to assess and quantize the human humoral immune response …

Reliable immunoassays are essential to early predict and monitor vaccine efficacy against
SARS-CoV-2. The performance of an Interferon Gamma Release Assay (IGRA …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus
responsible of the current pandemic ongoing all around the world. Since its discovery in …

Abstract Development of antibody protection during SARS-CoV-2 infection is a pressing
question for public health and for vaccine development. We developed highly sensitive …